GlassScriptPhysician profile
Crystal R Pietranton
NPI 1922451459
$9,435.28
in general payments reported to CMS, 2019-2025
17 companies · $7,205 in 2025
The $7,205 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $610 · 2023: $429 · 2024: $468 · 2025: $7,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,525 · Food and Beverage: $1,972 · Travel and Lodging: $1,578 · Education: $27.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,525.00 |
| Food and Beverage | $1,971.93 |
| Travel and Lodging | $1,577.58 |
| Education | $27.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,265.48 | 2022-2025 | Navitor, Amplatzer Amulet, Cardiomems |
| Medtronic, INC. | $832.68 | 2021-2025 | Corevalve Evolut R, Linq II |
| Boston Scientific Corporation | $749.28 | 2021-2023 | Watchman Access System |
| Edwards Lifesciences Corporation | $461.49 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $365.33 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $170.41 | 2021-2023 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $158.76 | 2023-2024 | |
| Abiomed | $136.34 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $64.71 | 2024 | Arcalyst |
| Cerus Corporation | $47.25 | 2024 | Intercept Blood System For Platelets |
| Actelion Pharmaceuticals US, INC. | $38.91 | 2022 | |
| Cvrx, INC. | $34.46 | 2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $30.58 | 2022 | |
| Heartflow, INC. | $24.37 | 2023 | Ffrct |
| Novo Nordisk INC | $22.19 | 2025 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $18.68 | 2024 | Gore Cardioform Septal Occluder |
| Pfizer INC. | $14.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Pietranton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.